High haemoglobin / haematocrit

Definition/Description

Investigation is suggested if the haematocrit is persistently (>2 months, preferably repeated without tourniquet) >0.52 (male) or >0.48 (female). This may be due to increased red cell mass (true polycythaemia) or reduced plasma volume (apparent polycythaemia). If the haematocrit is >0.6 (male) or >0.56 (female) then it can be assumed that there is a true increase in red cell mass.

Red Flag Symptoms

None provided

Guidelines on Management

Differential Diagnosis:

  • Apparent polycythaemia may be due to a variety of causes such as diuretics, heavy smoking or alcohol, dehydration, stress, oedema, hypertension or obesity.
  • True polycythaemia
    • Reactive to hypoxia - e.g. pulmonary disease, carbon monoxide / heavy smoking, sleep apnoea or congenital cyanotic heart disease.
    • Abnormal high erythropoietin - e.g. secondary to various tumours (e.g. renal carcinoma or hepatoma), renal transplant or renal artery stenosis.
    • Polycythaemia vera - bone marrow disorder with uncontrolled red cell proliferation. Usually positive for JAK2 V617F mutation. Associated with thrombotic and haemorrhagic complications. May be associated with generalised itch (classically after a hot shower or bath), splenomegaly or raised WCC / PLT.
    • Endocrine - Cushing's syndrome, Conn's syndrome, phaecochromocytoma or androgens (including testosterone supplements and anabolic steroids).
    • Inherited erythropoietin or haemoglobin variants (rare).

Examination:

  • Features of cardiac or pulmonary disease.
  • Features of hyperviscosity (fatigue, headache, slowed thought, muscosal / retinal bleeding, blurred / double vision, chest / abdominal pain, myalgia).
  • Splenomegaly suggests polycythaemia vera, although this is not consistent.

Baseline investigations:

  • FBC, U+E, LFT, ferritin (a high haematocrit despite low ferritin strongly suggests polycythaemia vera. DO NOT give iron replacement).
  • Review cardiovascular risk factors, although primary aspirin prophylaxis is not recommended unless PRV.
  • Further tests as indicated by history, e.g. oxygen saturations, PFT, CXR.

Referral Criteria/Information

Referral:

  • Review cardiovascular risk factors for all patients, regardless of cause.
  • Haematocrit persistently >0.52 (male) or >0.48 (female) without obvious cause or with suspicion of polycythaemia vera. URGENT referral if features of hyperviscosity.
  • Other referrals as directed by suspected cause, e.g. may benefit from long-term oxygen therapy or ACE-inhibitors if chronic hypoxia.

Additional Resources & Reference

Haematology Handbook - South Tees Hospitals NHS Foundation Trust
 

References:

McMullin MF, et al. A guideline for the investigation and management of polycythaemia vera. Br J Haematol 2018; doi.org/10.1111/bjh.15648

NICE Clinical Knowledge Summary. Polycythaemia / Erythrocytosis (September 2024). https://cks.nice.org.uk/polycythaemiaerythrocytosis 

Associated Policies

There are no associated policies.

Places covered by

  • North Yorkshire

Hospital Trusts

  • South Tees Hospitals